SBIA
TCON

Sheaff Brock Investment Advisors’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-63
Closed -$17K – 537
2019
Q1 		$17K Buy
+63
New +$13.6K ﹤0.01% 503

Other funds holding TCON

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Sheaff Brock Investment Advisors's TCON Position: Q2 2019 in Review

Sheaff Brock Investment Advisors sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2019, closing a stake of 63 shares — an estimated $17K sold.

Sheaff Brock Investment Advisors first reported a position in TCON in Q1 2019 and held it in 1 quarter. The position peaked at $17K in Q1 2019. 25 funds tracked by Wall St. Rank hold TCON as of Q2 2019.

  • Sheaff Brock Investment Advisors reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 63 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $17K.
  • Sheaff Brock Investment Advisors first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Sheaff Brock Investment Advisors's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $17K in Q1 2019.
  • 25 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Sheaff Brock Investment Advisors's 13F filing for Q2 2019, filed 31 Jul 2019.